Morning Briefing
Summaries of health policy coverage from major news organizations
To Weed Out Fraud, CMS Orders All States To Undergo Medicaid Audit
The Trump administration will require all 50 states to explain their plans to revalidate some of their Medicaid providers in a national escalation of anti-fraud efforts that have so far largely focused on specific states, Dr. Mehmet Oz said Tuesday. The Centers for Medicare and Medicaid Administrator said during a Politico health care summit that his agency plans to ask states to “own” the problem of health care fraud this week with requests for states to share their strategies within 30 days. (Swenson, 4/21)
On the high cost of prescription drugs —
The Trump administration had planned for insurers to provide cheap weight loss drugs to seniors through a Medicare pilot program. Insurers said no, so the government will instead cover the drugs outside of the Medicare Part D drug benefit. (Wilkerson, 4/21)
The top lobbyist for the pharmaceutical industry cautioned against President Donald Trump’s push to codify his most-favored-nation deals into law as the “wrong policy prescription,” but said he has “identified a real issue” in scrutiny of drug prices in the U.S. Even as he criticized codifying the high-profile agreements with 16 large drugmakers that Trump touts as a health care success, Pharmaceutical Research and Manufacturers of America CEO Stephen Ubl praised the administration’s efforts to convince other nations to increase what they pay for medicines. (Lim, 4/21)
More news about the Trump administration —
The F.B.I. believed the child was kidnapped by a transgender parent to potentially undergo gender transition surgery, according to court filings. (Ferré-Sadurní and Robles, 4/21)
California for now has prevented the Trump administration from changing priorities in homelessness funding to favor temporary shelters rather than long-term housing. (Kendall, 4/21)
Public colleges, K-12 schools, local governments and other public institutions will have an extra year to make their digital materials fully accessible for people with disabilities, according to the U.S. Department of Justice. Many institutions had been racing, for at least two years, toward a deadline that was originally set for this Friday to comply with new federal accessibility guidelines updating the Americans with Disabilities Act (ADA). It was a day disability rights advocates had been eagerly awaiting. (Mehta, 4/22)
Washington's anti-hospital animus is gaining momentum with new calls to crack down on federal financing of hospitals coming from a think tank with close ties to the Trump administration. (Owens, 4/22)
The Navy is appealing to doctors who are frustrated with the administrative side of practicing medicine, running a month-long marketing campaign to recruit top talent. The campaign ads target young doctors ages 26 to 32, as well as nurses and dentists, across four major cities: Chicago, Los Angeles, New York, and San Diego. (Fiore, 4/21)
People have plowed through savings, cashed out retirement funds and moved in with relatives. Former U.S.A.I.D. workers estimate that less than half have found full-time work. (Bumiller and Sullivan, 4/21)
How the Iran war is affecting medical supplies —
The world’s top condom producer, Malaysia’s Karex Bhd, plans to raise prices by 20% to 30% and possibly further if supply chain disruptions drag on due to the Iran war, its chief executive has said. Karex is also seeing a surge in condom demand as rising freight costs and shipping delays have left many of its customers with lower stockpiles than usual, CEO Goh Miah Kiat told Reuters in an interview on Tuesday. Karex produces more than 5 billion condoms annually and is a supplier to leading brands like Durex and Trojan. (Latiff, 4/21)
Reckitt Benckiser Group Plc reported weaker-than-expected sales on sluggish demand for its cold medicines in the US and as the conflict in the Middle East hit supplies in the region. Sales of its top brands including Strepsils lozenges and Dettol cleaning products rose 1.3% in the first quarter, Reckitt said Wednesday, short of the 2.8% expected by analysts. Excluding over-the-counter drugs in the US, growth was 3.1%, fueled by strong performance in China. (Deutsch, 4/22)